RT Journal Article
SR Electronic
T1 Predicted Norovirus Resurgence in 2021-2022 Due to the Relaxation of Nonpharmaceutical Interventions Associated with COVID-19 Restrictions in England: A Mathematical Modelling Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.09.21260277
DO 10.1101/2021.07.09.21260277
A1 Kathleen M O’Reilly
A1 Frank Sandman
A1 David Allen
A1 Christopher I Jarvis
A1 Amy Gimma
A1 Amy Douglas
A1 Lesley Larkin
A1 Kerry LM Wong
A1 Marc Baguelin
A1 Ralph S Baric
A1 Lisa C Lindesmith
A1 Richard A Goldstein
A1 Judith Breuer
A1 W John Edmunds
YR 2021
UL http://medrxiv.org/content/early/2021/09/03/2021.07.09.21260277.abstract
AB Background To reduce the coronavirus disease burden in England, along with many other countries, the Government implemented a package of non-pharmaceutical interventions (NPIs) that have also impacted other transmissible infectious diseases such as norovirus. It is unclear what future norovirus disease incidence is likely to look like upon lifting these restrictions.Methods Here we use a mathematical model of norovirus fitted to community incidence data in England to project forward expected incidence based on contact surveys that have been collected throughout 2020-2021.Results We report that susceptibility to norovirus infection has likely increased between March 2020 to mid-2021. Depending upon assumptions of future contact patterns incidence of norovirus that is similar to pre-pandemic levels or an increase beyond what has been previously reported is likely to occur once restrictions are lifted. Should adult contact patterns return to 80% of pre-pandemic levels the incidence of norovirus will be similar to previous years. If contact patterns return to pre-pandemic levels there is a potential for the expected annual incidence to be up to 2-fold larger than in a typical year. The age-specific incidence is similar across all ages.Conclusions Continued national surveillance for endemic diseases such as norovirus will be essential after NPIs are lifted to allow healthcare services to adequately prepare for a potential increase in cases and hospital pressures beyond what is typically experienced.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is a simulation, no data were collected as part of the studyFunding StatementThis research was primarily funded by the Wellcome Trust Noropatrol [grant code203268/Z/16/Z]. Additional funding is acknowledged from Public Health England (PHE) which is an executive agency of the Department of Health and Social Care (DHSC) and National Institute for Health USA (NIAID 1R01 AI148260). CoMix is funded by the EU Horizon 2020 Research and Innovations Programme - project EpiPose (Epidemic Intelligence to Minimize COVID-19s Public Health, Societal and Economical Impact No 101003688) and by the Medical Research Council (Understanding the dynamics and drivers of the COVID-2019 epidemic using real-time outbreak analytics MC_PC 19065).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was exempt from ethical approval because it is a simulation study, no data were collected as part of this research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code and data used to conduct these analyses are found at https://github.com/kath-o-reilly/norovirus_NPIs. For data access to the SGSS data used in the study applicants can apply to the PHE team by emailing noroOBK@phe.gov.uk https://github.com/kath-o-reilly/norovirus_NPIs IIDInfectious Intestinal DiseaseNPINon pharmaceutical interventionsSEIRsusceptible-exposed-infectious-recoveredSGSSSecond Generation Surveillance SystemUKUnited Kingdom